摘要
Abstract
Objective:To observe the clinical curative effect and safety of Shenqifuzheng Injection (SQFZI) in combination with SOX regimen on advanced gastric cancer.Methods:Sixty-one patients with advanced gastric cancer who were treated in our hospital between Nov.2013 and Nov.2015 were chosen as the research subjects,and were randomly divided into the observation group and the control group,with 31 and 30 cases respectively in each group.The ones in both groups were given SOX regimen for chemotherapy,and symptomatic supportive treatment,then the ones in the observation group were added SQFZI.Results:The observation group's RR was 74.19％,whilt that of the control group was 43.33％,the observation group was better than the control grouP(x2 =6.003,P =0.014 ＜ 0.05).The observation group's DCR was 93.55％,whilt that of the control group was 73.33％,the observation group was better than the control group(x2 =4.546,P =0.033 ＜ 0.05).The observation group's TTP and MST were better than those of the control group (P ＜ 0.0l).There were no treatment-related death in the two groups,and their toxicity to gastrointestinal reactions,bone marrow suppression and peripheral neurotoxicity were clear.The incidence of adverse reaction of the observation group was better than that of the control group (P ＜ 0.05 or 0.01).Conclusion:SQFZI in combination with SOX regimen has a remarkable clinical curative effect on advanced gastric cancer.The incidence of adverse reactions is low,and can improve the patients' quality of life and prolong their survival.关键词
晚期胃癌/参芪扶正注射液/SOX方案/替吉奥胶囊/奥沙利铂Key words
advanced gastric cancer/Shenqifuzheng Injection (SQFZI)/SOX regimen/S-1 Capsules/oxaliplatin分类
医药卫生
